Food and Drug Administration, HHS.
The Food and Drug Administration is correcting a notice entitled “Maximal Usage Trials for Topically Applied Active Ingredients Being Considered for Inclusion in an Over-the-Counter Monograph: Study Elements and Considerations; Guidance for Industry; Availability” that appeared in the Federal Register of May 10, 2019. The document announced the availability of a guidance for industry. The document was published with the incorrect docket number. This document corrects that error.
Start Further Info
FOR FURTHER INFORMATION CONTACT:
Kristen Hardin, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 22, Rm. 5443, Silver Spring, MD 20993-0002, 240-402-4246.
End Further Info
Start Supplemental Information
In the Federal Register of Friday, May 10, 2019 (84 FR 20633), in FR Doc. 2019-09692, the following correction is made:
On page 20633, in the first column, in the headings of the document, “[Docket No. FDA-2019-D-1798]” is corrected to read “[Docket No. FDA-2018-D-1456].”
End Supplemental Information
Dated: May 24, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019-11313 Filed 5-29-19; 8:45 am]
BILLING CODE 4164-01-P